Our previous clinical trials of low‐dose IL‐2 therapy in systemic lupus erythematosus and Sjogren's syndrome have demonstrated that it could enhance antigen‐independent expansions of Treg cells,36, 37, 38 thus providing a strategy to improve the poor clonal expansion of Treg cells in autoimmune uveitis. Here, IL2 is linked to Sjogren syndrome.